Squitieri & Fearon, LLP is investigating claims for people who suffered side effects after taking the leukemia drug Iclusig.
Since Iclusig was first approved by the U.S. Food and Drug Administration (FDA), the drug has been prescribed to treat chronic myeloid leukemia. On October 31, 2013, the FDA issued a Public Health Notification suspending the sale of Iclusig (also known as ponatinib), which has been linked to severe and sometimes fatal heath attacks, strokes, blindness and loss of blood flow in the extremities that can require amputation.
If you or a loved one suffered complications after taking the drug Iclusig, you may be eligible to file a suit. Please contact Stephen J. Fearon, Jr. by e-mail at stephen@sfclasslaw.com or by phone at (212) 421-6492. You can also complete the following form, and someone from the firm will contact you.